Literature DB >> 24831790

A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.

P Michael Conn1, Emery Smith, Timothy Spicer, Peter Chase, Louis Scampavia, Jo Ann Janovick.   

Abstract

We describe a phenotypic high throughput screening (HTS) calcium flux assay designed to identify pharmacoperones for the gonadotropin releasing hormone receptor (GnRHR). Pharmacoperones are target-specific, small molecules that diffuse into cells, rescue misfolded protein mutants, and restore them to function. Rescue is based on correcting the trafficking of mutants that would otherwise be retained in the endoplasmic reticulum and unable to function correctly. This approach identifies drugs with a significant degree of novelty, relying on cellular mechanisms that are not currently exploited. Development of such assays is important, since the extensive use of agonist/antagonist screens alone means that useful chemical structures may be present in existing libraries but have not been previously identified using existing methods. Our assay utilizes cell lines stably expressing a GnRHR mutant under the control of a tetracycline (OFF) transactivator. This allows us to quantitate the level of functional and properly trafficked G protein coupled receptors present in each test well. Furthermore, since we are able to turn receptor expression on and off, we can rapidly eliminate the majority of false positives from our screening results. Our data show that this approach is likely to be successful in identifying hits from large chemical libraries.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831790      PMCID: PMC4025569          DOI: 10.1089/adt.2014.576

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  77 in total

1.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

Authors:  V Heiser; E Scherzinger; A Boeddrich; E Nordhoff; R Lurz; N Schugardt; H Lehrach; E E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.

Authors:  Jian-Qiang Fan
Journal:  Trends Pharmacol Sci       Date:  2003-07       Impact factor: 14.819

Review 3.  GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies.

Authors:  Patrizia Limonta; Marina Montagnani Marelli; Stefania Mai; Marcella Motta; Luciano Martini; Roberta M Moretti
Journal:  Endocr Rev       Date:  2012-07-09       Impact factor: 19.871

Review 4.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

5.  Site-specific conformational studies of prion protein (PrP) amyloid fibrils revealed two cooperative folding domains within amyloid structure.

Authors:  Ying Sun; Leonid Breydo; Natallia Makarava; Qingyuan Yang; Olga V Bocharova; Ilia V Baskakov
Journal:  J Biol Chem       Date:  2007-01-23       Impact factor: 5.157

6.  Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists.

Authors:  W T Ashton; R M Sisco; Y T Yang; J L Lo; J B Yudkovitz; K Cheng; M T Goulet
Journal:  Bioorg Med Chem Lett       Date:  2001-07-09       Impact factor: 2.823

7.  Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for G protein-coupled receptor activation.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; P Michael Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-04-28       Impact factor: 4.030

8.  Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans.

Authors:  Alfredo Leaños-Miranda; Alfredo Ulloa-Aguirre; Tae H Ji; Jo Ann Janovick; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

9.  Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target.

Authors:  Jo Ann Janovick; Guadalupe Maya-Nunez; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

10.  Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.

Authors:  A M Comaru-Schally; W Brannan; A V Schally; M Colcolough; M Monga
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

View more
  4 in total

Review 1.  Assay strategies for identification of therapeutic leads that target protein trafficking.

Authors:  P Michael Conn; Timothy P Spicer; Louis Scampavia; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

Review 2.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

3.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

4.  Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity.

Authors:  Emery Smith; Jo Ann Janovick; Thomas D Bannister; Justin Shumate; Vadivel Ganapathy; Louis Scampavia; Timothy P Spicer
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.